Loading...You are here: Home > 'Avastin'
Study shows Amgen’s new biosimilar cancer drug safe, effective
Pharmaceuticals Amgen and Allergan announced positive Phase 3 study results of their new drug ABP 215 on Sept. 23. The drug, used to treat lung cancer, is being developed as a biosimilar to Roche Holding AG’s Avastin. ABP 215 showed clinical safety and effectiveness compared to Avastin. “Lung cancer is the leading cause of cancer Read More →